Do individuals with Factor V Leiden have an increased platelet count?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Factor V Leiden Does Not Cause Increased Platelet Count

No, individuals with Factor V Leiden do not have increased platelet counts. Factor V Leiden is a mutation affecting the coagulation cascade, specifically causing resistance to activated protein C, but it does not alter platelet production or numbers 1.

Understanding the Mechanism

Factor V Leiden (FVL) is a point mutation (G to A at nucleotide 1691) that results in a substitution at position 506 (Arg506Gln), making Factor Va resistant to inactivation by activated protein C 1. This leads to:

  • Prolonged procoagulant activity - Factor Va persists longer in circulation
  • Increased thrombin generation - More clot formation potential
  • No effect on platelet production - The mutation affects clotting factors, not megakaryocyte function or platelet release

The thrombophilia associated with FVL results from hypercoagulability in the plasma coagulation system, not from platelet abnormalities 1.

What the Research Shows About Platelets and FVL

While FVL doesn't increase platelet count, some interesting platelet-related findings exist:

  • Platelet microparticles may be elevated in FVL carriers, which could contribute to thrombotic risk, but this reflects platelet activation, not increased platelet numbers 2, 3
  • Mean platelet volume (MPV) has been studied as a potential biomarker for identifying high-risk thrombophilia patients, but this measures platelet size, not count 4
  • Platelet aggregation responses appear normal or even decreased in pregnant women with FVL, with no difference in platelet function compared to non-carriers 5

Clinical Implications

When evaluating a patient with FVL:

  • Do not expect thrombocytosis - A complete blood count will show normal platelet numbers
  • If thrombocytosis is present, investigate other causes (myeloproliferative disorders, reactive thrombocytosis, etc.)
  • The thrombotic risk comes from the coagulation cascade dysfunction, not platelet abnormalities 1

Common Clinical Pitfall

Do not confuse the increased thrombotic risk in FVL with conditions that cause thrombocytosis (like essential thrombocythemia or polycythemia vera). These are entirely different mechanisms:

  • FVL: Normal platelet count + hypercoagulable plasma
  • Myeloproliferative disorders: Elevated platelet count + abnormal platelet function

The 5-7 fold increased risk of venous thromboembolism in FVL heterozygotes (and 50-100 fold in homozygotes) stems entirely from impaired anticoagulant function, not from platelet abnormalities 6, 1.

References

6
Research

Factor V Leiden with deep venous thrombosis.

Clinical laboratory science : journal of the American Society for Medical Technology, 2003

Related Questions

Is glutathione indicated for patients with factor V deficiency or factor V Leiden hypercoagulability, and does it affect clotting parameters or interact with anticoagulant therapy?
In a female patient with a hematocrit of 47.2% and a mean platelet volume of 11.2 fL, with otherwise normal laboratory results, what is the appropriate evaluation and management?
What laboratory screening should be performed for a patient with multiple deep vein thromboses (DVT), including testing for the factor V Leiden mutation?
What does a mean platelet volume of 8.9 fL indicate when the complete blood count is otherwise normal?
Is eosinophilic esophagitis genetic?
What is the next treatment option for a patient with moderate depression who has failed adequate trials of citalopram, sertraline, escitalopram, duloxetine, and venlafaxine?
What is the efficacy of tavaborole 5% solution for achieving clearance of mild‑to‑moderate distal or lateral subungual onychomycosis in a healthy patient?
For hypoattenuated leaflet thickening, should we continue apixaban and clopidogrel lifelong?
What is the recommended dose of cromolyn sodium (Crome) injection for treating bleeding?
How long does the self‑limited viral exanthem affecting the face, neck, and trunk in an otherwise well‑appearing patient who has regained appetite typically persist?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.